SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Solid Biosciences (NASDAQ:SLDB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
Profitability
This table compares SOPHiA GENETICS and Solid Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -102.84% | -47.40% | -34.54% |
| Solid Biosciences | N/A | -53.76% | -43.74% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for SOPHiA GENETICS and Solid Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 3 | 0 | 2.75 |
| Solid Biosciences | 0 | 0 | 8 | 1 | 3.11 |
Institutional and Insider Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 13.6% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
SOPHiA GENETICS has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Earnings and Valuation
This table compares SOPHiA GENETICS and Solid Biosciences’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $64.94 million | 3.83 | -$78.98 million | ($1.12) | -3.39 |
| Solid Biosciences | $8.09 million | 41.51 | -$96.01 million | ($3.94) | -2.22 |
SOPHiA GENETICS has higher revenue and earnings than Solid Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Solid Biosciences beats SOPHiA GENETICS on 10 of the 15 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About Solid Biosciences
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
